Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Estimating the contribution of BRCA2 to hereditary ovarian cancers in the French Canadian population of Quebec.

FY 2011-12

Summary
Ovarian cancer has a survival rate of less than 30%. There are no screening methods for the detection of early stage disease when treatment is most effective, and there are few available effective treatment options. About 10% of cases are due to the inheritance of mutations in the genes BRCA1 and BRCA2, but this varies with population. Identifying carriers of BRCA1/2 mutations allows for earlier cancer screening and prevention options, and qualifies such individuals for the emerging BRCA1/2-specific anti-cancer drugs. The proposed project seeks to determine what proportion of French Canadian women in Quebec with ovarian cancer have mutations in the BRCA2 gene, and thus might benefit from BRCA1/2-specific anti-cancer drug treatment. Our findings may allow more French Canadian women to qualify for early cancer screening programs and targeted treatment, with the goal of increasing cancer prevention among the population as a whole.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
252426
Name
Dolman Lena
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Estimating the contribution of BRCA2 to hereditary ovarian cancers in the French Canadian population of Quebec.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brca2; Cancer Genetics; Cancer Susceptibility; Founder Effects; French Canadian Population; Ovarian Cancer; Recurrent Mutations
Abstract
Ovarian cancer has a survival rate of less than 30%. There are no screening methods for the detection of early stage disease when treatment is most effective, and there are few available effective treatment options. About 10% of cases are due to the inheritance of mutations in the genes BRCA1 and BRCA2, but this varies with population. Identifying carriers of BRCA1/2 mutations allows for earlier cancer screening and prevention options, and qualifies such individuals for the emerging BRCA1/2-specific anti-cancer drugs. The proposed project seeks to determine what proportion of French Canadian women in Quebec with ovarian cancer have mutations in the BRCA2 gene, and thus might benefit from BRCA1/2-specific anti-cancer drug treatment. Our findings may allow more French Canadian women to qualify for early cancer screening programs and targeted treatment, with the goal of increasing cancer prevention among the population as a whole.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dolman, Lena
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~